论文部分内容阅读
目的探讨慢性粒细胞白血病(CML)采用酪氨酸激酶抑制剂(TKI)治疗临床效果。方法 100例慢性粒细胞白血病患者,依据病程分为慢性期组(80例)、加速期组(10例)、急变期组(10例)。均采用TKI治疗。观察并比较三组疗效。结果全部患者完全血液学缓解(CHR)率为92.0%,细胞遗传学缓解(MCy R)率为76.0%,完全细胞遗传学缓解(CCy R)率为73.1%,分子学缓解(MMR)率为47.9%。慢性期组有效率为80.0%,加速期组有效率为60.0%,急变期组有效率为30.0%,三组比较差异有统计学意义(P<0.05)。慢性期组、加速期组、急变期组总生存率(OS)比较差异无统计学意义(P>0.05),但5年无事件生存(EFS)率慢性期组明显长于其他两组,差异有统计学意义(P<0.05)。结论针对慢性粒细胞白血病患者,采用酪氨酸激酶抑制剂治疗,可显著提高临床效果,延长患者生存时间。临床需重视病情的评估,对不同药物剂量进行选择,以最大程度改善预后。
Objective To investigate the clinical effect of treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitor (TKI). Methods One hundred patients with chronic myeloid leukemia were divided into chronic phase group (n = 80), accelerated phase group (n = 10) and blastic phase group (n = 10) according to their course of disease. TKI treatment are used. Observed and compared the efficacy of three groups. Results The complete hematological response (CHR) rate was 92.0%, the cytogenetic response (MCy R) rate was 76.0%, the complete cytogenetic response (CCy R) rate was 73.1%, and the MMR rate was 47.9%. The effective rate was 80.0% in chronic phase group, 60.0% in accelerated phase group and 30.0% in acute phase group. The difference between the three groups was statistically significant (P <0.05). There was no significant difference in the overall survival rate between the chronic phase group, the accelerated phase group and the abrupt phase group (P> 0.05), but the 5-year event-free survival (EFS) rate in the chronic phase group was significantly longer than that in the other two groups Statistical significance (P <0.05). Conclusion The treatment of chronic myeloid leukemia patients with tyrosine kinase inhibitors can significantly improve the clinical effect and prolong the survival time of patients. Clinical needs to pay attention to the assessment of the disease, the choice of different drug doses to maximize prognosis.